Biogen Inc. (BIIB) stock
BIIBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 28, 2026Score 4/3056% above fair value
$250.79−0.86 (-0.34%)
Close on Nov 17, 2026Market cap $37.07BP/E 107.2Yield –
Biogen r&d expenses
Research and development expenses are spending on new products and technology.
Biogen's R&D Expenses for the twelve months ending Sep 30, 2026 was $2.15B, up 20.7% year over year. For fiscal 2025 it was $1.78B, down 10.2% from the year before. Over ten years it grew -1.2% a year on average. The highest annual figure on record is $3.99B in fiscal 2020.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.78B | -10.2% |
| FY2024 | Dec 31, 2024 | $1.98B | -19.0% |
| FY2023 | Dec 31, 2023 | $2.45B | +9.6% |
| FY2022 | Dec 31, 2022 | $2.23B | -10.8% |
| FY2021 | Dec 31, 2021 | $2.50B | -37.3% |
| FY2020 | Dec 31, 2020 | $3.99B | +75.0% |
| FY2019 | Dec 31, 2019 | $2.28B | -12.2% |
| FY2018 | Dec 31, 2018 | $2.60B | +15.2% |
| FY2017 | Dec 31, 2017 | $2.25B | +14.2% |
| FY2016 | Dec 31, 2016 | $1.97B | -2.0% |
| FY2015 | Dec 31, 2015 | $2.01B | +6.3% |
| FY2014 | Dec 31, 2014 | $1.89B | +31.1% |
| FY2013 | Dec 31, 2013 | $1.44B | +8.2% |
| FY2012 | Dec 31, 2012 | $1.33B | +9.5% |
| FY2011 | Dec 31, 2011 | $1.22B | -2.3% |
| FY2010 | Dec 31, 2010 | $1.25B | -2.7% |
| FY2009 | Dec 31, 2009 | $1.28B | +19.7% |
| FY2008 | Dec 31, 2008 | $1.07B | +15.9% |
| FY2007 | Dec 31, 2007 | $925.16M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $574.00M | +31.6% |
| Q2 FY2026 | Jun 30, 2026 | $529.60M | +32.7% |
| Q1 FY2026 | Mar 31, 2026 | $539.00M | +24.2% |
| Q4 FY2025 | Dec 31, 2025 | $509.40M | -0.8% |
| Q3 FY2025 | Sep 30, 2025 | $436.10M | -15.5% |
| Q2 FY2025 | Jun 30, 2025 | $399.00M | -21.1% |
| Q1 FY2025 | Mar 31, 2025 | $434.10M | -2.5% |
| Q4 FY2024 | Dec 31, 2024 | $513.30M | -7.4% |
| Q3 FY2024 | Sep 30, 2024 | $516.20M | -29.9% |
| Q2 FY2024 | Jun 30, 2024 | $505.40M | -13.5% |
| Q1 FY2024 | Mar 31, 2024 | $445.40M | -21.9% |
| Q4 FY2023 | Dec 31, 2023 | $554.30M | -7.9% |
| Q3 FY2023 | Sep 30, 2023 | $736.30M | +34.1% |
| Q2 FY2023 | Jun 30, 2023 | $584.20M | +10.5% |
| Q1 FY2023 | Mar 31, 2023 | $570.60M | +3.4% |
| Q4 FY2022 | Dec 31, 2022 | $601.60M | -14.0% |
| Q3 FY2022 | Sep 30, 2022 | $549.20M | -21.8% |
| Q2 FY2022 | Jun 30, 2022 | $528.60M | -9.7% |
| Q1 FY2022 | Mar 31, 2022 | $551.70M | +7.3% |
| Q4 FY2021 | Dec 31, 2021 | $699.50M | -59.5% |
| Q3 FY2021 | Sep 30, 2021 | $702.40M | -38.4% |
| Q2 FY2021 | Jun 30, 2021 | $585.10M | -9.7% |
| Q1 FY2021 | Mar 31, 2021 | $514.20M | +8.0% |
| Q4 FY2020 | Dec 31, 2020 | $1.73B | +149.5% |
| Q3 FY2020 | Sep 30, 2020 | $1.14B | +111.1% |
| Q2 FY2020 | Jun 30, 2020 | $647.60M | +33.6% |
| Q1 FY2020 | Mar 31, 2020 | $476.30M | -15.5% |
| Q4 FY2019 | Dec 31, 2019 | $691.70M | +13.1% |
| Q3 FY2019 | Sep 30, 2019 | $540.40M | +6.4% |
| Q2 FY2019 | Jun 30, 2019 | $484.80M | -50.6% |
| Q1 FY2019 | Mar 31, 2019 | $563.70M | +13.5% |
| Q4 FY2018 | Dec 31, 2018 | $611.60M | +4.1% |
| Q3 FY2018 | Sep 30, 2018 | $507.90M | +13.8% |
| Q2 FY2018 | Jun 30, 2018 | $981.00M | +23.2% |
| Q1 FY2018 | Mar 31, 2018 | $496.70M | +17.3% |
| Q4 FY2017 | Dec 31, 2017 | $587.60M | +10.1% |
| Q3 FY2017 | Sep 30, 2017 | $446.40M | – |
| Q2 FY2017 | Jun 30, 2017 | $796.20M | – |
| Q1 FY2017 | Mar 31, 2017 | $423.40M | – |
| Q4 FY2016 | Dec 31, 2016 | $533.90M | – |
See a number that looks wrong?